治疗晚期肺癌合并间质性肺病的现有药物疗法:文献综述与未来展望。

IF 0.7 Q4 MEDICINE, RESEARCH & EXPERIMENTAL JOURNAL OF MEDICAL INVESTIGATION Pub Date : 2024-01-01 DOI:10.2152/jmi.71.9
Masaki Hanibuchi, Hirokazu Ogino, Seidai Sato, Yasuhiko Nishioka
{"title":"治疗晚期肺癌合并间质性肺病的现有药物疗法:文献综述与未来展望。","authors":"Masaki Hanibuchi, Hirokazu Ogino, Seidai Sato, Yasuhiko Nishioka","doi":"10.2152/jmi.71.9","DOIUrl":null,"url":null,"abstract":"<p><p>Patients with interstitial lung disease (ILD), especially those with idiopathic pulmonary fibrosis, are at increased risk of developing lung cancer (LC). Pharmacotherapy for advanced LC has dramatically progressed in recent years;however, management of LC with pre-existing ILD (LC-ILD) is challenging due to serious concerns about the risk of acute exacerbation of ILD (AE-ILD). As patients with LC-ILD have been excluded from most prospective clinical trials of advanced LC, optimal pharmacotherapy remains to be elucidated. Although the antitumor activity of first-line platinum-based cytotoxic chemotherapy appears to be similar in advanced LC patients with or without ILD, its impact on the survival of patients with LC-ILD is limited. Immune checkpoint inhibitors may hold promise for long-term survival, but many challenges remain, including safety and appropriate patient selection. Further understanding the predictive factors for AE-ILD after receiving pharmacotherapy in LC-ILD may lead to appropriate patient selection and lower treatment risk. The aim of this review was to summarize the current evidence related to pharmacotherapy for advanced LC-ILD and discuss emerging areas of research. J. Med. Invest. 71 : 9-22, February, 2024.</p>","PeriodicalId":46910,"journal":{"name":"JOURNAL OF MEDICAL INVESTIGATION","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Current pharmacotherapies for advanced lung cancer with pre-existing interstitial lung disease : A literature review and future perspectives.\",\"authors\":\"Masaki Hanibuchi, Hirokazu Ogino, Seidai Sato, Yasuhiko Nishioka\",\"doi\":\"10.2152/jmi.71.9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Patients with interstitial lung disease (ILD), especially those with idiopathic pulmonary fibrosis, are at increased risk of developing lung cancer (LC). Pharmacotherapy for advanced LC has dramatically progressed in recent years;however, management of LC with pre-existing ILD (LC-ILD) is challenging due to serious concerns about the risk of acute exacerbation of ILD (AE-ILD). As patients with LC-ILD have been excluded from most prospective clinical trials of advanced LC, optimal pharmacotherapy remains to be elucidated. Although the antitumor activity of first-line platinum-based cytotoxic chemotherapy appears to be similar in advanced LC patients with or without ILD, its impact on the survival of patients with LC-ILD is limited. Immune checkpoint inhibitors may hold promise for long-term survival, but many challenges remain, including safety and appropriate patient selection. Further understanding the predictive factors for AE-ILD after receiving pharmacotherapy in LC-ILD may lead to appropriate patient selection and lower treatment risk. The aim of this review was to summarize the current evidence related to pharmacotherapy for advanced LC-ILD and discuss emerging areas of research. J. Med. Invest. 71 : 9-22, February, 2024.</p>\",\"PeriodicalId\":46910,\"journal\":{\"name\":\"JOURNAL OF MEDICAL INVESTIGATION\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JOURNAL OF MEDICAL INVESTIGATION\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2152/jmi.71.9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JOURNAL OF MEDICAL INVESTIGATION","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2152/jmi.71.9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

间质性肺病(ILD)患者,尤其是特发性肺纤维化患者,罹患肺癌(LC)的风险更高。近年来,针对晚期肺癌的药物治疗取得了显著进展;然而,由于对肺癌急性加重(AE-ILD)风险的严重担忧,对已存在 ILD 的肺癌患者(LC-ILD)的治疗极具挑战性。由于大多数晚期 LC 的前瞻性临床试验都将 LC-ILD 患者排除在外,因此最佳的药物治疗方法仍有待阐明。尽管以铂类为基础的一线细胞毒化疗在有或没有ILD的晚期LC患者中的抗肿瘤活性似乎相似,但其对LC-ILD患者生存期的影响有限。免疫检查点抑制剂可能为长期生存带来希望,但仍存在许多挑战,包括安全性和适当的患者选择。进一步了解LC-ILD患者接受药物治疗后出现AE-ILD的预测因素,可帮助患者做出适当选择并降低治疗风险。本综述旨在总结与晚期LC-ILD药物治疗相关的现有证据,并讨论新出现的研究领域。J. Med.Invest.71 : 9-22, February, 2024.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Current pharmacotherapies for advanced lung cancer with pre-existing interstitial lung disease : A literature review and future perspectives.

Patients with interstitial lung disease (ILD), especially those with idiopathic pulmonary fibrosis, are at increased risk of developing lung cancer (LC). Pharmacotherapy for advanced LC has dramatically progressed in recent years;however, management of LC with pre-existing ILD (LC-ILD) is challenging due to serious concerns about the risk of acute exacerbation of ILD (AE-ILD). As patients with LC-ILD have been excluded from most prospective clinical trials of advanced LC, optimal pharmacotherapy remains to be elucidated. Although the antitumor activity of first-line platinum-based cytotoxic chemotherapy appears to be similar in advanced LC patients with or without ILD, its impact on the survival of patients with LC-ILD is limited. Immune checkpoint inhibitors may hold promise for long-term survival, but many challenges remain, including safety and appropriate patient selection. Further understanding the predictive factors for AE-ILD after receiving pharmacotherapy in LC-ILD may lead to appropriate patient selection and lower treatment risk. The aim of this review was to summarize the current evidence related to pharmacotherapy for advanced LC-ILD and discuss emerging areas of research. J. Med. Invest. 71 : 9-22, February, 2024.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
JOURNAL OF MEDICAL INVESTIGATION
JOURNAL OF MEDICAL INVESTIGATION MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
1.20
自引率
0.00%
发文量
55
期刊最新文献
Changes in intestinal microbiota and biochemical parameters in patients with inflammatory bowel disease and irritable bowel syndrome induced by the prolonged addition of soluble fibers to usual drug therapy. Characterization of Outer Membrane Vesicles Produced by Vibrio vulnificus. Clarification of Psychiatric Nurses' Intentions and Analysis Contents in Observing Schizophrenia Patient. Current pharmacotherapies for advanced lung cancer with pre-existing interstitial lung disease : A literature review and future perspectives. Feasibility of laparoscopic and endoscopic cooperative surgery for gastric gastrointestinal stromal tumor with tumor diameter of >5 cm.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1